```
Sign in Subscribe
By Ainvest in options-flow —

UTHR: $13.3M Complex Trades Detected (Oct 29)

Massive $13.3M institutional bullish positioning detected on UTHR. Complete breakdown includes whale positioning analysis, gamma exposure levels, and risk-adjusted trading ideas for retail traders.

UTHR $13.3M Multi-Leg Strategy After Earnings Pop - Institutional Bet on IPF Approval!

📅 October 29, 2025 | 🔥 Complex Institutional Activity Detected

🎯 The Quick Take

A sophisticated trader just deployed a $13.3M three-legged options strategy on United Therapeutics at 9:45 AM today, right after the stock surged 9.6% following Q3 earnings! This isn't a simple directional bet - it's a measured bullish call spread with downside protection positioned for the company's blockbuster TETON-2 trial results in idiopathic pulmonary fibrosis (IPF) and potential FDA approval through early 2026. Translation: Smart money is betting on continued momentum while protecting downside risk!

📊 Company Overview

United Therapeutics Corporation (UTHR) specializes in drug development for pulmonary arterial hypertension (PAH) and rare lung diseases:
- Market Cap: $18.78 Billion
- Industry: Pharmaceutical Preparations
- Current Price: $455.32 (up 9.6% today, +26.4% YTD)
- Primary Business: Developing and commercializing treatments for rare cardiopulmonary diseases, particularly pulmonary hypertension and lung diseases based on treprostinil

💰 The Option Flow Breakdown

The Tape (October 29, 2025 @ 09:45:00):

Time Symbol Side Buy/Sell Type Expiration Premium Strike Volume OI Size Spot Option Price Option Symbol
09:45:00 UTHR MID SELL PUT 2026-01-16 $3.8M $420 3.0K 3 3,050 $452.62 $12.56 UTHR20260116P420
09:45:00 UTHR MID BUY CALL 2026-01-16 $6.8M $470 3.0K 4 3,050 $452.62 $22.20 UTHR20260116C470
09:45:00 UTHR MID SELL CALL 2026-01-16 $2.5M $510 3.0K 10 3,050 $452.62 $8.14 UTHR20260116C510

🤓 What This Actually Means

This is a sophisticated risk reversal with a call spread - not your typical directional bet! Here's the breakdown:

  • 💸 Total capital involved: $13.3M across three simultaneous legs
  • 📊 Net cost: $0.5M ($6.8M paid - $3.8M collected - $2.5M collected)
  • 🎯 Structure: Short $420 put + Long $470 call + Short $510 call
  • ⏰ Time horizon: 79 days to January 16, 2026 expiration
  • 🏦 Institutional signature: 3,050 contracts (305,000 shares worth ~$138M) executed simultaneously at midpoint

What's really happening here:

This trader is making a measured bullish bet on UTHR's pipeline while managing risk intelligently:

  1. Sold $420 put (collected $3.8M): Willing to buy shares at $420 if stock pulls back 7.2%. This generates premium income and reflects confidence the stock won't collapse below $420.

  2. Bought $470 call (paid $6.8M): This is the core bullish bet - profits above $470 (3.8% above current price). Cost basis of $22.20 per share shows expectation of continued upside.

  3. Sold $510 call (collected $2.5M): Caps maximum profit at $510 (12.7% above current price). This reduces the net cost of the position and suggests the trader expects gains but not unlimited upside.

The trade thesis: Stock moves from $455 → $470-$510 range over next 79 days, capturing the TETON-1 trial readout expected H1 2026 and FDA submission momentum. Maximum profit of ~$11.7M if UTHR reaches $510; maximum risk if stock collapses below $420 (forced to buy at $420 when market is lower).

Unusual Score: 🔥 INSTITUTIONAL DESK TRADE - This three-legged strategy executed with 3,050 contracts simultaneously signals sophisticated hedge fund or proprietary trading desk activity. The $13.3M total capital commitment represents a measured institutional bet on UTHR's pipeline catalysts.

📈 Technical Setup / Chart Check-Up

YTD Performance Chart

UTHR YTD Performance

United Therapeutics is crushing it this year with +26.4% YTD returns, currently trading at $455.32. The chart tells a remarkable recovery and momentum story:

Key observations:
- 📈 Strong momentum: Massive rally from ~$270 in August to $455+ today - that's a 68% surge in just 3 months!
- 💹 Recent breakout: Fresh all-time highs following today's 9.6% earnings pop on Q3 record revenue of $799.5M and TETON-2 breakthrough
- 🎢 Volatility: 52.3% annualized vol reflects the biotech nature - big swings are the norm
- 📊 Max drawdown: -27.86% earlier this year shows the stock can pull back hard (March dip to ~$270)
- 🚀 Volume spike: Massive volume today (off the charts) confirms institutional interest in the earnings pop

The September-October rally coincided with the TETON-2 Phase 3 trial announcement showing 95.6 mL improvement in lung function for IPF patients - a potential game-changer worth billions.

Gamma-Based Support & Resistance Analysis

UTHR Gamma S/R

Current Price: $455.32

The gamma exposure map shows critical price magnets and barriers for options-driven trading:

🔵 Support Levels (Put Gamma Below Price):
- $450 - Strongest nearby support with 0.69B total gamma (just 1.2% below) - this is the immediate floor
- $440 - Secondary support at 0.17B gamma (3.4% below)
- $430 - Solid support zone with 0.55B gamma (5.6% below)
- $410 - Deep support at 0.36B gamma (10.0% below) - major put wall here

🟠 Resistance Levels (Call Gamma Above Price):
- $470 - STRONGEST resistance with 0.70B gamma (3.2% above) - this matches the long call strike!
- $480 - Secondary ceiling at 0.23B gamma (5.4% above)
- $490 - Major resistance zone with 0.50B gamma (7.6% above)
- $500 - Extended resistance at 0.62B gamma (9.8% above)

What this means for traders:

The gamma data reveals something critical - the $470 resistance level (0.70B gamma) perfectly aligns with the bought call strike in today's option flow! This isn't coincidence. The trader structured this position knowing $470 is a significant gamma barrier where market makers will hedge by selling stock, creating natural resistance.

However, if UTHR breaks through $470 on strong volume (positive catalyst like FDA feedback or TETON-1 data preview), the next clear path is to $490-$500 - which explains why the $510 call was sold (capping upside just above the $500 resistance).

The strong support at $450 provides downside cushion, while the $420 put reflects willingness to own shares 7.2% lower - well below the $430-$440 support cluster.

Net GEX Bias: Bullish (3.60B call gamma vs 1.15B put gamma) - Overall positioning heavily favors the upside with 3:1 call-to-put ratio.

Implied Move Analysis

UTHR Implied Move

Options market pricing for upcoming expirations:

  • 📅 Monthly OPEX (Nov 21 - 23 days): ±$30.22 (±6.64%) → Range: $425.10 - $485.54
  • 📅 Quarterly Triple Witch (Dec 19 - 51 days): ±$40.50 (±8.90%) → Range: $414.82 - $495.82

Translation for regular folks:

Options traders are pricing in a 6.6% move ($30) by November expiration and an 8.9% move ($41) through December. That's pretty standard volatility for a biotech stock with major catalysts ahead!

The November upper range of $485.54 sits nicely between the $470 long call and $510 short call, suggesting the market thinks there's a reasonable chance UTHR trades in this range. The December upper range of $495.82 approaches the $500 gamma resistance, aligning with realistic upside targets.

Importantly, the lower range of $425 by November provides context for the $420 put strike - it's positioned just below the expected downside range, offering true protection against unexpected negative developments.

🎪 Catalysts

🔥 Past Catalysts (Already Happened)

Q3 2025 Earnings - October 29, 2025 (TODAY!) 📊

UTHR reported Q3 results this morning, triggering the 9.6% surge:

Market reaction: Despite slight revenue miss, investors focused on the TETON-2 implications announced in September, driving today's surge.

TETON-2 IPF Phase 3 Trial Breakthrough - September 2, 2025 ✅

The game-changer that's driving institutional positioning:

CEO Martine Rothblatt called it "unlocking new hope for patients with IPF" - and Wall Street agrees this could add $1+ billion in annual revenue.

$1 Billion Share Repurchase Program - August 2025 💵

Management signaled massive confidence with aggressive buyback:

🚀 Upcoming Catalysts (Next 6-12 Months)

TETON-1 Trial Readout - H1 2026 (MASSIVE!) 🎯

The biggest near-term catalyst driving the options positioning:

This catalyst directly aligns with the January 16, 2026 option expiration - the position expires right before or during TETON-1 readout window!

FDA Submission & Approval Process - 2026 📋

Following positive TETON-1 results:

Ralinepag Phase 3 ADVANCE OUTCOMES Trial 💊

Another potential blockbuster in the pipeline:

Xenotransplantation Program - 2025-2026 🧬

Pioneering technology that could revolutionize organ transplants:

This is moonshot technology with potentially massive long-term value but high execution risk.

Next Earnings Report - February 25, 2026 📊

Q4 2025 earnings expected to show:
- Analyst consensus: $6.19 EPS
- Full-year results including holiday quarter performance
- Updated guidance on IPF launch timing and market sizing
- Competition dynamics with Liquidia's Yutrepia

⚠️ Risk Catalysts (Negative)

Liquidia's Yutrepia Competition - Active Threat 😰

The biggest near-term competitive risk:

Impact assessment: While management dismisses Yutrepia as "undifferentiated", the early adoption data suggests real market share pressure on the core Tyvaso franchise. However, the IPF expansion opportunity could more than offset PAH/PH-ILD losses.

Pipeline Competition 🏥

  • Insmed's TPIP: Once-daily treprostinil powder showing promise in Phase 2 - superior convenience
  • Liquidia's L606: Next-generation twice-daily treprostinil suspension, pivotal trial planned late 2025
  • Merck's Winrevair: New PAH competitor adding market pressure

Regulatory Risks ⚖️

🎲 Price Targets & Probabilities

Using gamma levels, implied move data, catalysts, and today's options positioning, here are the scenarios:

📈 Bull Case (40% probability)

Target: $490-$510

How we get there:
- 💪 TETON-1 trial readout in H1 2026 validates TETON-2 results, confirming $1B+ IPF opportunity
- 🚀 FDA provides positive feedback on sNDA submission timeline
- 📊 Q4 2025 earnings show resilient Tyvaso performance despite Yutrepia competition
- 💊 Ralinepag Phase 3 data preview or positive investigator commentary emerges
- 🧬 Xenotransplantation program reports successful patient outcomes
- 📈 Breakthrough gamma resistance at $470-$480 levels on sustained catalyst-driven buying
- 🏦 Institutional accumulation continues following today's flow

This is the sweet spot for the options trade: Stock reaches $490-$510, the call spread ($470-$510) captures maximum profit of ~$11.7M. The $510 short call caps upside at exactly the upper bull case target.

Key metrics: From $455 current price to $500 midpoint = 9.9% gain aligning with quarterly implied move of 8.9%.

🎯 Base Case (45% probability)

Target: $450-$480 range

Most likely scenario:
- ✅ Continued digestion of TETON-2 breakthrough and Q3 earnings beat
- 📱 No major negative surprises on Yutrepia competition - management's 5% market share estimate proves accurate
- ⏰ TETON-1 data timing confirmed for H1 2026, maintaining positive sentiment
- 🔄 Trading within strong gamma support ($450) and resistance ($470-$480) bands
- 📊 Q4 earnings meet expectations, guidance remains constructive
- 💰 $1B share buyback provides price floor support

Trade outcome: Stock stays in range, the $470 long call approaches break-even or modest profit, $420 put expires worthless. Modest profit of $1-5M possible depending on exact price at expiration.

This is a "waiting game" scenario: The January expiration might be too early to capture full TETON-1 impact (likely March-June readout), so the trade consolidates gains from today's pop without major new catalysts.

📉 Bear Case (15% probability)

Target: $400-$430

What could go wrong:
- 😰 Yutrepia competition proves more aggressive than expected - Q4 market share data shows 20%+ capture
- 📉 TETON-1 trial delayed or preview data raises questions about replication
- ⚖️ FDA feedback letter requests unexpected additional studies for IPF approval
- 💸 Broader biotech sector selloff drags all names lower regardless of fundamentals
- 🏥 Competitor announces breakthrough alternative IPF therapy
- 📊 Q4 earnings disappoint on revenue guidance or margin compression
- 🛡️ Key support: Strong gamma support at $430-$440 and put wall at $410 should limit downside

Trade outcome: Stock falls to $400-$430 range, approaching the $420 put strike. Trader would be forced to buy 305,000 shares at $420 when market is $400-$430, creating unrealized loss of $3-6M on the shares, plus the $0.5M net debit paid = total loss of $3.5-6.5M. However, calls expire worthless limiting upside loss.

Important note: The $420 put strike is positioned 7.2% below current price and well below the November implied move lower range ($425), providing reasonable downside buffer. The trader clearly believes this scenario is unlikely.

💡 Trading Ideas

🛡️ Conservative: Wait for TETON-1 Data Strategy

Play: Stay on sidelines until TETON-1 results announced in H1 2026

Why this works:
- ⏰ Major binary catalyst 3-6 months away - too much uncertainty to commit now
- 💸 Stock already up 26.4% YTD and 68% from August lows - significant gains priced in
- 📊 Valuation at $18.78B market cap requires successful IPF launch to justify
- 🎯 Better entry likely on pullback to $430-$440 gamma support or after TETON-1 news
- 🏥 Yutrepia competition still playing out - need more quarterly data to assess impact

Action plan:
- 👀 Monitor TETON-1 trial updates and FDA communication
- 🎯 Watch for pullback to $430 support level for stock entry
- ✅ Confirm Tyvaso maintains market position despite Yutrepia in Q4 earnings
- 📊 Review analyst commentary after February 25, 2026 earnings

Risk level: Minimal (cash position) | Skill level: Beginner-friendly

⚖️ Balanced: Shares with Covered Calls

Play: Buy 100-200 shares at current levels, sell covered calls at $480-$500

Structure:
- Buy 100 shares of UTHR at ~$455 = $45,500 capital
- Sell 1x February 2026 $480 calls for ~$20-25 premium (estimate)
- Hold through Q4 earnings (Feb 25) and into TETON-1 data window

Why this works:
- 📈 Participate in upside to $480 (+5.4%) while collecting premium
- 🛡️ Premium income provides downside cushion
- 🎯 Captures value if stock consolidates in $450-$480 range (base case)
- ⏰ February expiration gives time for Q4 earnings and possible TETON-1 preview
- 📊 Less capital intensive than the $13.3M institutional trade but similar thesis

Estimated P&L:
- 📈 Max profit: ~$2,500-$2,700 per 100 shares if called away at $480 (5.4% gain + $20-25 premium)
- 💰 Breakeven: ~$435 (cost basis minus premium collected)
- 📉 Max loss: Shares could fall to $400-$430 support; loss cushioned by premium

Exit strategy:
- Roll calls higher if stock breaks $480 on strong catalyst
- Close position if stock approaches $430 support
- Hold through TETON-1 data if timing aligns

Risk level: Moderate (defined upside, stock downside risk) | Skill level: Intermediate

🚀 Aggressive: Mimic the Institutional Trade (HIGH RISK!)

Play: Replicate the three-legged strategy but with smaller size

Structure: Short put + Long call + Short call spread (January 16, 2026 expiration)
- Sell 1-2x $420 puts (collect ~$12.56 per share)
- Buy 1-2x $470 calls (pay ~$22.20 per share)
- Sell 1-2x $510 calls (collect ~$8.14 per share)

Why this could work:
- 🏦 Following smart institutional money that deployed $13.3M on same thesis
- 🎯 Structured for $470-$510 upside (aligning with gamma resistance and bull case)
- 💰 Net debit only ~$1.50 per share ($150 per full spread) for potential $4,000 profit
- ⏰ 79 days captures TETON-1 data timing window or at least momentum building into it
- 📊 Defined maximum profit and risk parameters

Why this could blow up (SERIOUS RISKS):
- 💥 PUT ASSIGNMENT RISK: If UTHR drops below $420, you're forced to buy 100 shares per contract at $420 = $42,000 capital requirement per contract
- 😱 Yutrepia competition could worsen dramatically, driving stock to $380-$400 range
- 🚀 TETON-1 data might not come until after January expiration (March-June window), leaving position to expire before catalyst
- ⚖️ Biotech volatility - unexpected negative news could gap stock down 15-20%
- 💰 Requires significant margin/capital to secure short put obligations
- 📉 Loss accelerates below $420: Every $1 drop = $100 loss per contract on forced share purchase

Estimated P&L (per 1-contract spread):
- 💰 Net debit: ~$150 ($2,220 paid - $1,256 collected - $814 collected)
- 📈 Max profit: ~$3,850 if UTHR at $510+ at expiration (($510-$470) × 100 - $150)
- 📉 Max loss: SUBSTANTIAL - if stock at $400, forced to buy at $420, immediate $2,000 unrealized loss per contract plus $150 debit = $2,150 total
- ⚠️ Breakeven: ~$471.50 on upside; ~$418.50 on downside (put strike minus net debit)

Position sizing: Start with 1-2 contracts maximum to limit risk exposure to $4,200-$8,400 capital requirement if assigned.

Risk level: HIGH (substantial put assignment risk) | Skill level: Advanced only

⚠️ WARNING: DO NOT attempt this trade unless you:
- Understand risk reversals and multi-leg option strategies
- Can handle buying 100 shares per contract at $420 ($42,000 per contract)
- Have experience managing biotech volatility and binary events
- Can monitor and adjust position if stock moves against you
- Accept that January expiration might be too early for TETON-1 catalyst

⚠️ Risk Factors

Don't get caught by these potential landmines:

  • ⏰ TETON-1 timing uncertainty: Results expected H1 2026 (March-June), which might be after the January 16 option expiration. The institutional trade could be too early for the catalyst or betting on momentum building into the data readout. If results come in June, the January options expire without capturing the value.

  • 💸 Valuation after 68% run: Stock has surged from $270 in August to $455 today - massive gains already captured. Trading at $18.78B market cap, UTHR needs to execute flawlessly on IPF launch worth $1B+ annually to justify current levels. Limited margin for error.

  • 🏥 Yutrepia competitive threat intensifying: Over 900 prescriptions in first 11 weeks shows real adoption. If Yutrepia captures 20-45% market share instead of management's projected 5%, core Tyvaso revenue could decline significantly. Q4 earnings will be critical data point.

  • ⚖️ FDA approval risk for IPF: While TETON-2 results were overwhelmingly positive, TETON-1 must replicate findings. FDA could request additional studies, impose restrictive labeling, or delay approval timeline. Any setback would materially impact valuation given IPF opportunity is now priced in.

  • 💊 Pipeline competition accelerating: Insmed's once-daily TPIP and Liquidia's L606 represent next-generation competition with superior convenience. If these competitors advance faster than expected, UTHR's window to capture IPF market could narrow. Merck's Winrevair also pressuring PAH franchise.

  • 🎢 Biotech sector volatility: 52.3% annualized volatility and -27.86% max drawdown YTD show this stock can move violently. Broader biotech selloffs, changes in risk appetite, or sector rotation could drive 15-20% declines regardless of UTHR-specific fundamentals. The March 2025 dip to $270 proves downside risk is real.

  • 💰 Put assignment risk for short strategies: The $420 put in the institutional trade requires ability to purchase $42,000 worth of stock per contract (or $128M for the full 3,050 contracts!). Retail traders attempting similar strategies must have adequate capital and margin. Stock dropping to $380-$400 creates immediate substantial unrealized losses.

  • 📊 Gamma ceiling at $470 resistance: Strong call gamma (0.70B) at $470 means market makers will sell into rallies to hedge, creating natural price cap. Would need significant sustained buying pressure or major positive catalyst to break through. The institutional trader structured the long call at exactly this resistance level - breakout not guaranteed.

  • 🧬 Xenotransplantation program execution risk: While revolutionary technology, organ transplant trials carry high failure risk. Adverse events or rejection issues could create negative headlines. This is moonshot value, not near-term catalyst.

  • 📅 Q4 earnings execution on February 25, 2026: Falls right in the middle of the option expiration window. If Q4 results disappoint on Tyvaso performance or margin compression, stock could pull back to $420-$430 support, threatening put strikes. Conversely, strong results could provide launching pad toward $480-$500 targets.

🎯 The Bottom Line

Real talk: A sophisticated institutional player just deployed a $13.3M three-legged options strategy on the same day UTHR surged 9.6% on earnings and TETON-2 breakthrough implications. This isn't euphoric chasing - it's a measured, intelligent bet structured for $470-$510 upside over the next 79 days.

What this trade tells us:
- 🎯 Smart money expects UTHR to continue higher toward $470-$510 range (matching gamma resistance levels)
- 💰 They're willing to own shares at $420 if wrong, showing conviction this is the floor
- ⚖️ Risk/reward is favorable for capturing TETON-1 momentum building into H1 2026 data
- 📊 The $0.5M net debit for potential $11.7M profit shows asymmetric setup (23:1 risk/reward ratio if max profit achieved)

If you own UTHR:
- ✅ Consider taking partial profits after 26.4% YTD gain - stock up 68% from August lows
- 📊 Strong gamma support at $450 provides cushion, but Yutrepia competition risk and biotech volatility means 15-20% pullbacks are possible
- ⏰ Hold if you believe in TETON-1 delivering positive results in H1 2026 and can stomach volatility
- 🎯 Set mental stop at $430 (strong gamma support) to protect gains
- 💰 Today's 9.6% pop provides opportunity to trim without FOMO

If you're watching from sidelines:
- ⏰ February 25, 2026 Q4 earnings is first key date - watch Tyvaso performance vs Yutrepia
- 🎯 Pullback to $430-$440 support would offer better risk/reward entry (5-6% correction from current levels)
- 📈 Looking for confirmation that TETON-2's 95.6 mL improvement wasn't a fluke - TETON-1 data is the proof
- 🚀 Longer-term (6-18 months), IPF approval and launch in 2026-2027 is a legitimate multi-billion dollar catalyst
- ⚠️ Current valuation requires successful execution - low margin for error

If you're bearish:
- 🎯 Wait for Q4 earnings data on Yutrepia impact before initiating short positions
- 📊 First meaningful support at $450 (gamma wall), major support at $430-$440
- ⚠️ Watch for TETON-1 trial delays or FDA feedback that raises questions
- 📉 Put spreads ($450/$430 or $440/$420) offer defined risk way to play downside
- ⏰ Be patient - fighting momentum after 9.6% earnings pop and TETON-2 breakthrough is dangerous

Mark your calendar - Key dates:
- 📅 February 25, 2026 - Q4 FY2025 earnings report (98 days away)
- 📅 January 16, 2026 - Option expiration for the $13.3M institutional trade (79 days away)
- 📅 March-June 2026 - TETON-1 trial results expected (H1 2026 window)
- 📅 Mid-2026 - Potential FDA sNDA submission for IPF indication following TETON-1
- 📅 Late 2026/Early 2027 - Possible FDA approval and commercial launch of Tyvaso for IPF

Final verdict: This institutional trade is betting that UTHR's momentum from TETON-2 success continues through early 2026 as TETON-1 data approaches. The structure ($420 put / $470-$510 call spread) is intelligent - defined risk, asymmetric reward, positioned around key gamma levels. However, the January expiration might be too early to capture actual TETON-1 results, making this more of a "sentiment into catalyst" play than a "catalyst itself" play.

For retail investors, the lesson is clear: wait for better risk/reward setups. A pullback to $430-$440 offers 5-6% better entry with strong gamma support underneath. Alternatively, be patient for actual TETON-1 data before committing capital - the IPF opportunity is real, but execution must be proven. The stock has run hard (+68% in 3 months), and while the thesis is compelling, valuation leaves little room for disappointment.

If you do trade this, respect the volatility, size positions appropriately, and understand that biotech binary events can create 15-20% moves in either direction overnight. The $13.3M institutional player has the capital and risk management sophistication to handle assignment risk and adverse moves - most retail traders don't. Learn from the structure, but adjust for your own risk tolerance and capital constraints.

Disclaimer: Options trading involves substantial risk of loss and is not suitable for all investors. This analysis is for educational purposes only and not financial advice. Past performance doesn't guarantee future results. The unusual score reflects trade size relative to recent history - it does not imply the trade will be profitable or that you should follow it. Biotech stocks carry elevated risk due to clinical trial outcomes, regulatory decisions, and competitive dynamics. Always do your own research and consider consulting a licensed financial advisor before trading. Short put strategies carry obligation to purchase shares at strike price, requiring adequate capital and margin.

About United Therapeutics Corporation: United Therapeutics specializes in drug development for pulmonary arterial hypertension (PAH) and rare lung diseases with a $18.78 billion market cap in the Pharmaceutical Preparations industry. The company develops therapies centered on the prostacyclin pathway, with several treatments based on treprostinil, and is pioneering xenotransplantation technology for organ transplants.

Subscribe to AInvest Option Labs

Don’t miss out on the latest issues. Sign up now to get access to the library of members-only issues.
jamie@example.com
Subscribe